ניופוגן mu 48 מזרק מוכן לשימוש
amgen europe b.v. - filgrastim - תמיסה להזרקה - filgrastim 48 mu / 0.5 ml - filgrastim - filgrastim - - reduction in the duration and severity of neutropenia in patients treated with highly myelosuppressive chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes ).- reduction in the duration of neutropenia in patients undergoing high-dose cytotoxic chemotherapy followed by bone marrow transplantation. - in children or adults with severe congenital neutropenia cyclic neutropenia or idiopathic neutropenia a history of clinically important infections within the last 12 months and three documented episodes of neutropenia (with an anc< 5 x 1000000000) long-term administration of neupogen is indicated to increase neutrophil counts and to reduce infections. - neupogen is indicated for the mobilisation of autologous peripheral blood progenitor cells alone or following myelosuppressive chemotherapy and the mobilisation of peripheral blood progenitor cells in normal donors (allogeneic pbpc).
ניופוגן mu 30 מזרק מוכן לשימוש
amgen europe b.v. - filgrastim - תמיסה להזרקה - filgrastim 30 mu / 0.5 ml - filgrastim - filgrastim - - reduction in the duration and severity of neutropenia in patients treated with highly myelosuppressive chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes ).- reduction in the duration of neutropenia in patients undergoing high-dose cytotoxic chemotherapy followed by bone marrow transplantation. - in children or adults with severe congenital neutropenia cyclic neutropenia or idiopathic neutropenia a history of clinically important infections within the last 12 months and three documented episodes of neutropenia (with an anc< 5 x 1000000000) long-term administration of neupogen is indicated to increase neutrophil counts and to reduce infections. - neupogen is indicated for the mobilisation of autologous peripheral blood progenitor cells alone or following myelosuppressive chemotherapy and the mobilisation of peripheral blood progenitor cells in normal donors (allogeneic pbpc).
אוורל 50
truemed ltd. - estradiol as hemihydrate - מדבקות - estradiol as hemihydrate 3.2 mg - estradiol
אקופיל 300 מקג0.5 מל
tzamal bio-pharma ltd - filgrastim - תמיסה להזרקה\אינפוזיה - filgrastim 300 mcg / 0.5 ml - filgrastim
אקופיל 480 מקג0.5 מל
tzamal bio-pharma ltd - filgrastim - תמיסה להזרקה\אינפוזיה - filgrastim 480 mcg / 0.5 ml - filgrastim
ורזניו 200 מג
eli lilly israel ltd, israel - abemaciclib - טבליות מצופות פילם - abemaciclib 200 mg - abemaciclib
סטימופיל 300 מקג0.5 מל
tzamal bio-pharma ltd - filgrastim - תמיסה להזרקה\אינפוזיה - filgrastim 300 mcg / 0.5 ml - filgrastim
סטימופיל 480 מקג0.5 מל
tzamal bio-pharma ltd - filgrastim - תמיסה להזרקה\אינפוזיה - filgrastim 480 mcg / 0.5 ml - filgrastim
קומדין 1 מג
taro pharmaceutical industries ltd - warfarin sodium - טבליה - warfarin sodium 1 mg - warfarin - warfarin - coumadin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, and pulmonary embolism. coumadin is indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement. coumadin is indicated to reduce the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after myocardial infarction.
קומדין 2 מג
taro pharmaceutical industries ltd - warfarin sodium - טבליה - warfarin sodium 2 mg - warfarin - warfarin - coumadin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, and pulmonar embolism. coumadin is indicated for the prophylaxis and/or treatment of the tromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement. coumadin is indicated to reduce the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after myocardial infarction.